OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Southeast University, China200 enrolled

Overview

This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Myocardial Ischemia-Reperfusion Injury

Interventions

Blood Biomarker Profiling and Prognostic Follow-upDIAGNOSTIC_TEST

Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period. 2. Age 18-90 years inclusive. Exclusion Criteria: 1. Active systemic infections. 2. Advanced heart failure (NYHA class III-IV). 3. Acute cerebrovascular conditions. 4. Active myocarditis. 5. cardiomyopathy. 6. Refractory ventricular tachycardia/fibrillation. 7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ). 8. Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m2 or dialysis dependence). 9. Child-Pugh class C hepatic dysfunction.

Outcomes

Primary Outcomes

Major Adverse Cardiovascular Events

Major Adverse Cardiovascular Events (MACEs) defined as the composite endpoint of recurrent acute myocardial infarction, cardiac death, stroke, hospitalization for unstable angina, or unplanned coronary revascularization.

Time frame: From enrollment to 44 months after reperfusion injury

Secondary Outcomes

Serum IL-1α Level

Units: pg/mL

Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)

Serum IL-1β Level

Units: pg/mL

Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)

Plasma Malondialdehyde (MDA) Level

Units: μmol/L

Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)

Plasma Hydrogen Peroxide (H₂O₂) Level

Units: μmol/L

Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)

OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts